Study guide
3.1 Viable Airborne Microbial Monitoring
BCSCP Board Certified Sterile Compounding Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview, USP Standards & CSP Categories
1.1 BCSCP Exam Format, Eligibility, Scoring & 2024 Content Outline 1.2 USP <797> Scope, Core Philosophy & Regulatory Framework 1.3 USP <797> Categories 1, 2, and 3 CSP Classification 1.4 Immediate-Use CSPs: The 4-Hour Rule and Its Conditions
2 Chapter 2: Facilities, Engineering Controls & Cleaning
2.1 Cleanroom Architecture & ISO Classifications 2.2 Primary Engineering Controls (PECs) & Laminar Airflow Dynamics 2.3 Segregated Compounding Areas (SCAs) & Containment SCAs (C-SCAs) 2.4 HVAC Engineering Controls, Pressure Differentials & Air Exchange 2.5 Equipment & Materials in Classified Areas Under Dynamic Conditions 2.6 Cleaning, Disinfecting, Sporicidal Agents & Sterile 70% IPA 2.7 Contingency Planning: Power, HVAC, Supply and Staffing Failures
3 Chapter 3: Environmental Monitoring & Facility Certification
3.1 Viable Airborne Microbial Monitoring 3.2 Total Airborne Non-Viable Particle Counting & Cleanroom Certification Standards 3.3 Surface Microbial Sampling: Contact Plates, Swabs, Incubation Protocols & Action Levels 3.4 Environmental Sampling Excursions, Trend Analysis, and Remediation Protocols
4 Chapter 4: Hand Hygiene, Garbing & Aseptic Technique
4.1 Hand Hygiene & Cleansing Protocols 4.2 Step-by-Step Garbing Sequence & Ante-Room Logistics 4.3 Direct Compounding Area (DCA) Aseptic Technique & First Air Integrity
5 Chapter 5: Beyond-Use Dating, Storage & Container Rules
5.1 Category 1 Beyond-Use Dating & Storage Limitations 5.2 Category 2 Beyond-Use Dating: Sterile vs. Nonsterile Starting Components 5.3 Category 3 Beyond-Use Dating: Requirements for Extended Dating (60/90/120 Days) 5.4 Container Types, Puncture Limits & Multi-Dose Container Rules
6 Chapter 6: Sterilization, Release Testing & Hazardous Drug Compounding
6.1 Terminal Sterilization vs. Sterilizing Filtration 6.2 Release Testing: Sterility (USP <71>), Endotoxin (USP <85>) & Particulates (USP <788>) 6.3 Container Closure Integrity Testing (CCIT) & Visual Inspection 6.4 USP <800> Hazardous Drug Compounding & Closed System Drug-Transfer Devices (CSTDs)
7 Chapter 7: Materials, Equipment & Compounding Workflow
7.1 Compounding Equipment & Technology: ACDs, Balances, Pumps & IV Workflow Systems 7.2 Compounding Supplies, Containers & Closures 7.3 Component Receipt, Storage & Material Transfer 7.4 Calibration, Verification, Validation & Maintenance of Equipment 7.5 Compounding Workflow: SOPs, Workflow Software, Production Queues & Labeling 7.6 Handling, Storing, Packaging, Transporting & Disposing of Finished CSPs
8 Chapter 8: Calculations, Osmolarity & Physicochemical Compatibility
8.1 Sterile Compounding Calculations: Millimoles, Milliequivalents, Osmolarity & Tonicity Adjustments 8.2 Physical and Chemical Incompatibilities: pH Effects, Salt Formations & Precipitation Mechanisms 8.3 Complex Admixture Compatibility: Calcium-Phosphate Solubility Curves & Parenteral Nutrition Dynamics
9 Chapter 9: Therapeutics, Administration & Patient Monitoring
9.1 Patient-Specific Parameters: Verifying CSP Orders 9.2 Special Administration Routes: Epidural, Intrathecal, Ophthalmic & Intravesical Sterile Preparations 9.3 Medication Delivery Devices, Home Infusion & Patient Education 9.4 High-Alert Sterile Medications, Pediatric/Neonatal Considerations & Extravasation Management 9.5 Therapeutic Drug Monitoring, Catheter-Related Bloodstream Infection (CRBSI) Prevention & Clinical Vigilance 9.6 Medication Adherence in Home and Outpatient Sterile Therapy 9.7 Interprofessional Care Coordination for Sterile Preparations
10 Chapter 10: Quality Management, Records & Personnel Competency
10.1 Master Formulation Records (MFR) vs. Compounding Records (CR) Requirements & Workflow 10.2 Personnel Training, Core Competency & Written Testing Requirements 10.3 Gloved Fingertip and Thumb Sampling (GFT) Testing Cadence, Pass/Fail Thresholds & Action Plans 10.4 Media-Fill Testing Protocols: Simulation Design, Incubation Parameters & Failure Investigations 10.5 Standard Operating Procedures & Document Control 10.6 Quality Assurance & Quality Control Programs 10.7 Inspection Methods, Self-Audits & Continuous Readiness 10.8 Literature Evaluation: Research Methods, Statistics & Stability Evidence
11 Chapter 11: Regulatory Oversight, Accreditation & Drug Supply Chain
11.1 Drug Quality and Security Act (DQSA) & FDA Section 503A Traditional Pharmacies vs. Section 503B Outsourcing Facilities 11.2 State Boards of Pharmacy, FDA Guidance & Inter-Agency Regulatory Jurisdictions 11.3 Drug Supply Chain Security Act (DSCSA), Component Qualification & Certificate of Analysis (CoA) Verification 11.4 CMS, The Joint Commission, CDC, ASPEN & ASHP: Standards Beyond USP and FDA
12 Chapter 12: Safety Management, Investigations, Recalls & Waste
12.1 Root Cause Analysis (RCA), CAPA Framework & Out-of-Specification (OOS) Investigations 12.2 Adverse Drug Event Reporting, FDA MedWatch Form 3500 & Product Recall Protocols 12.3 Occupational Safety, Hazardous Waste Disposal (RCRA / EPA) & Spill Clean-up Management
3.1 Viable Airborne Microbial Monitoring
Key Takeaways Explain This Topic AI
Viable air monitoring counts colony-forming units (CFUs) with an impaction air sampler that collects 1 cubic meter (1,000 liters) at each location; settle plates cannot substitute.
USP <797> requires viable air sampling of all classified areas under dynamic conditions at least every 6 months for Category 1 and 2 compounding. For Category 3, it is required within 30 days before starting and at least monthly afterward.
Air samples use a general growth medium such as TSA, incubated at 30-35 °C for at least 48 hours and then at 20-25 °C for at least 5 more days. Alternatively, two media devices can be incubated at the two temperatures at the same time.
Air action levels are >1 CFU/m³ for ISO Class 5, >10 CFU/m³ for ISO Class 7 and >100 CFU/m³ for ISO Class 8. Exceeding one requires investigation, corrective action, and an attempt to identify the organism to genus.
Last updated: September 2026
Principles of Active Volumetric Air Sampling
Viable airborne monitoring is a fundamental component of the environmental quality assurance program in sterile compounding. While non-viable particle counters detect total particulate burden, viable air sampling specifically detects and enumerates living microorganisms (bacteria and fungi) suspended in the air. The revised USP General Chapter <797> explicitly mandates active volumetric air sampling and strictly prohibits the use of passive settling plates (agar plates left open to air) as a primary method for viable air evaluation.
Volumetric Air Sampling Mechanics
Active air samplers draw a measured volume of air through a perforated sieve or slit orifice, accelerating particles so that viable microorganisms impact onto a nutrient agar surface.
Sample Volume : USP <797> requires an impaction air sampler to collect 1 cubic meter (1,000 liters) of air at each sampled location. USP's FAQ adds that settle plates may not be used instead.
Impaction Velocity : The sampler's velocity must be calibrated to ensure microbial impaction without shearing, desiccating, or lysing viable microbial cells upon contact with the agar.
Sampling Locations : Sampling sites must be chosen in every classified area: each ISO Class 5 PEC, plus the ISO Class 7 and 8 rooms. In an SCA, that means the PEC. The SOP must include a diagram of the locations, the sample size, and when samples are taken relative to compounding activity. Samplers must be serviced and calibrated as the manufacturer recommends.
Sampling Frequencies & Operational Conditions
Under USP <797> (2023 revision), the minimum frequencies for active viable airborne sampling are legally defined:
- Facility Tier Minimum Mandated Frequency Dynamic vs. Static Conditions
- Category 1 Facilities At least every 6 months Dynamic operating conditions
- Category 2 Facilities At least every 6 months Dynamic operating conditions
Category 3 Facilities Within 30 days before any Category 3 compounding starts, then at least monthly, whether or not Category 3 CSPs are being made Dynamic operating conditions
All Facilities (Ad Hoc) With certification of new facilities and equipment; after servicing (including HEPA filter changes); in response to problems (e.g., positive sterility tests) or trends (e.g., repeated GFT or media-fill failures); and after changes such as a new cleaning agent Dynamic operating conditions
Important
Viable environmental sampling must be performed under dynamic operating conditions —meaning during actual compounding activities or simulated operations with personnel present and equipment operating. Static testing (empty rooms) fails to capture the true microbial challenge introduced by staff presence and movement.
Growth Media and Incubation Regimens
To ensure recovery of environmental isolates exposed to cleaning agents and cleanroom sanitizers, specific nutrient formulations are required:
General Growth Media : Trypticase Soy Agar (TSA) (or Soybean-Casein Digest Medium) is the standard medium for bacterial recovery.
Media Quality : For air sampling, USP <797> requires a general microbiological growth medium that supports both bacteria and fungi. The manufacturer's certificate of analysis (COA) must confirm growth promotion, pH and sterilization. Neutralizing additives such as lecithin and polysorbate 80 are required for surface sampling media, because those plates touch disinfectant residue (see 3.3).
Fungal Media : Malt Extract Agar (MEA) , Sabouraud Dextrose Agar (SDA), or equivalent fungal-selective media are utilized to support mold and yeast growth, particularly in Category 3 suites or facilities with a history of fungal recovery.
Dual-Temperature Incubation Protocol
USP <797> accommodates dual-temperature incubation using TSA to detect both environmental bacteria and fungi:
First Phase : Incubate at 30°C to 35°C for no less than 48 hours (bacteria, including human-associated Gram-positive cocci).
Second Phase : Then incubate at 20°C to 25°C for no less than 5 additional days (fungi and slower environmental organisms).
USP says the higher temperature comes first because starting low can compromise recovery of Gram-positive cocci. To shorten the total time, two media devices may be collected at each location and incubated concurrently: one at 30-35°C for at least 48 hours and the other at 20-25°C for at least 5 days.
The incubator must be outside the sterile compounding area, and its temperature must be monitored and documented during incubation.
Action Levels for Viable Airborne Particles
USP <797> defines specific action levels based on the number of colony-forming units (CFUs) recovered per cubic meter ( 1 , 000 liters 1,000\text{ liters} 1 , 000 liters ) of sampled air. Exceeding these thresholds triggers an immediate mandatory investigation.
- Area Classification Air Cleanliness Designation Viable Airborne Action Level (CFU/m³ or CFU/1,000 L)
- ISO Class 5 Primary Engineering Control (LAFW, BSC, CAI, CACI) > 1 CFU
- ISO Class 7 Buffer Room, Ante-room (negative pressure suite) > 10 CFU
- ISO Class 8 Ante-room (positive pressure suite) > 100 CFU
Unclassified Segregated Compounding Area (SCA) room air No USP numeric level; the PEC inside the SCA is held to ISO Class 5 (> 1 CFU)
Warning
In an ISO Class 5 PEC, 2 CFU per cubic meter already exceeds the > 1 action level and requires investigation and corrective action. The 2008 chapter also required immediate remediation of highly pathogenic organisms (Gram-negative rods, coagulase-positive staphylococci, molds and yeasts) regardless of count. The current chapter instead ties the corrective action plan to both the CFU count and the organism recovered, and it requires regular trend review. Many facilities still write an objectionable-organism response into their SOPs.
Microbial Identification and Highly Objectionable Organisms
Numerical counts are only half of environmental surveillance. When an air or surface result exceeds its action level, USP <797> requires an attempt to identify the recovered organisms to the genus level , with a microbiologist's help. Below the action level, identification is not required, but it helps when trending shows a problem.
Many facility SOPs label certain taxa objectionable , a practice carried over from the 2008 chapter, and investigate them even at a single colony ( 1 CFU 1\text{ CFU} 1 CFU ) in an ISO Class 5 PEC or ISO Class 7 room. Commonly listed groups include:
Gram-Negative Bacilli: Organisms such as Pseudomonas aeruginosa , Burkholderia cepacia , Enterobacter cloacae , Klebsiella pneumoniae , and Serratia marcescens . These waterborne environmental bacteria shed lipopolysaccharide (LPS) endotoxins from their outer membranes, which can induce fatal septic shock, pyrogenic reactions, and disseminated intravascular coagulation when administered intravenously.
Coagulase-Positive Staphylococci: Specifically Staphylococcus aureus , indicating severe human touch contamination, respiratory shedding, or failure of personal garbing and mask integrity.
Filamentous Molds and Fungi: Genera such as Aspergillus , Penicillium , Cladosporium , Fusarium , and Rhizopus . Fungal spores are resilient to standard sanitizers, indicating potential HVAC filter breaches, water damage, or raw material introduction.
Yeasts: Such as Candida albicans or Rhodotorula , reflecting human commensal shedding or persistent wet harbourage sites.
Clinical Compounding Scenario: Microbial Recovery in an ISO 5 Workstation
Consider a high-volume sterile compounding pharmacy compounding batch cardioplegia solutions. During semi-annual certification under dynamic operating conditions, active volumetric air sampling within an ISO Class 5 horizontal laminar airflow workstation recovers 2 CFU / m 3 2\text{ CFU}/\text{m}^3 2 CFU / m 3 on a TSA impaction plate. Subsequent microbiological analysis identifies both colonies as Burkholderia cepacia , a Gram-negative bacillus.
This finding triggers an immediate, multi-step regulatory response:
Immediate Operational Halt: The Designated Person immediately orders all compounding within that specific workstation halted.
Product Quarantine and Risk Assessment: All compounded sterile preparations prepared inside the workstation since the last verified passing environmental monitoring cycle are placed into quarantined storage. The clinical pharmacy specialist reviews the beyond-use dates (BUDs) and distribution logs to determine if any units were dispensed to intensive care units.
Root Cause Analysis (RCA): The facility investigates potential moisture sources, as Burkholderia thrives in aqueous environments. Technicians inspect sink splash guards, water lines to automated compounding devices, disinfectant dilution systems, and HEPA filter integrity.
Sporicidal Decontamination and Re-sampling: The workstation is cleaned, disinfected and treated with a sterile sporicidal disinfectant, then sampled again under dynamic conditions. USP requires the follow-up data to be reviewed to confirm the corrective action worked. Compounding resumes when the Designated Person has reviewed those results and closed the investigation.